All shown data, together with the potential anthracycline cardiotoxicity and risk of anthracycline-induced leukemias in patients with a high probability of being cured, challenge the role of anthracyclines in the treatment of early stage TNBC patients. The combination of taxanes and platinum salts is, therefore, increasingly used as neoadjuvant chemotherapy for triple negative breast cancer. The docetaxel-carboplatin (TCb) regimen is an active and tolerable regimen in metastatic and locally advanced breast cancer, and the efficacy and toxicity characterization in the clinical setting are regaining interest in the era where the role of anthracyclines is controversial in the adjuvant setting. The avoidance of potentially serious long-term toxicities in specific breast cancer subtypes is a real challenge in an attempt to individualize therapies.